About: Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a population-based sample from Geneva, Switzerland

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a population-based sample from Geneva, Switzerland Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a population-based sample from Geneva, Switzerland
Creator	Pittet, Didier Chappuis, François Meyer, Benjamin Eckerle, Isabella Flahault, Antoine Trono, Didier Yerly, Sabine Azman, Andrew Arm Vernez, Isabelle Baysson, Hélène De Ridder, David Guessous, Idris Gétaz, Laurent Hurst, Samia Keiser, Olivia Lauer, Marcus1, Petrovic, Dusan Piumatti, Giovanni Schrempft, Stephanie Stringhini, Silvia Vuilleumier, Nicolas Wisniak, Ania
Source	MedRxiv
abstract	Background: Assessing the burden of COVID-19 based on medically-attended case counts is suboptimal given its reliance on testing strategy, changing case definitions and the wide spectrum of disease presentation. Population-based serosurveys provide one avenue for estimating infection rates and monitoring the progression of the epidemic, overcoming many of these limitations. Methods: Taking advantage of a pool of adult participants from population-representative surveys conducted in Geneva, Switzerland, we implemented a study consisting of 8 weekly serosurveys among these participants and their household members older than 5 years. We tested each participant for anti-SARS-CoV-2-IgG antibodies using a commercially available enzyme-linked immunosorbent assay (Euroimmun AG, Lubeck, Germany). We estimated seroprevalence using a Bayesian regression model taking into account test performance and adjusting for the age and sex of Geneva's population. Results: In the first three weeks, we enrolled 1335 participants coming from 633 households, with 16% <20 years of age and 53.6% female, a distribution similar to that of Geneva. In the first week, we estimated a seroprevalence of 3.1% (95% CI 0.2-5.99, n=343). This increased to 6.1% (95% CI 2.6-9.33, n=416) in the second, and to 9.7% (95% CI 6.1-13.11, n=576) in the third week. We found that 5-19 year-olds (6.0%, 95% CI 2.3-10.2%) had similar seroprevalence to 20-49 year olds (8.5%, 95%CI 4.99-11.7), while significantly lower seroprevalence was observed among those 50 and older (3.7%, 95% CI 0.99-6.0, p=0.0008). Interpretation: Assuming that the presence of IgG antibodies is at least in the short-term associated with immunity, these results highlight that the epidemic is far from burning out simply due to herd immunity. Further, no differences in seroprevalence between children and middle age adults are observed. These results must be considered as Switzerland and the world look towards easing restrictions aimed at curbing transmission.
has issue date	2020-05-06(xsd:dateTime)
bibo:doi	10.1101/2020.05.02.20088898
has license	medrxiv
sha1sum (hex)	4ccb28268e3b1758976ea69ada6f605e5f3946e6
schema:url	https://doi.org/10.1101/2020.05.02.20088898
resource representing a document's title	Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a population-based sample from Geneva, Switzerland
resource representing a document's body	covid:4ccb28268e3b1758976ea69ada6f605e5f3946e6#body_text
is schema:about of	named entity 'COVID-19' named entity 'testing' named entity 'preprint' named entity 'certified' named entity 'reliance' named entity 'estimating' named entity 'antibodies' named entity 'CC-BY-NC-ND 4.0' named entity 'IgG antibodies' named entity 'preprint' named entity 'Germany' named entity 'preprint' named entity 'Switzerland' named entity 'preprint' named entity 'preprint' named entity 'antibodies' named entity 'canton of Geneva' named entity 'seroprevalence' named entity 'epidemics' named entity 'Lübeck' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'seroprevalence' named entity 'SARS-CoV-2' named entity 'health policy makers' named entity 'immunocompromised' named entity 'World Health Organization' named entity 'seroprevalence' named entity 'preprint' named entity 'RT-PCR' named entity 'sensitivity analysis' named entity 'SARS-CoV-2' named entity 'Europe' named entity 'preprint' named entity 'seroprevalence' named entity 'virus' named entity 'medRxiv' named entity 'randomly selected' named entity 'seroprevalence' named entity 'medRxiv' named entity 'study population' named entity 'preprint' named entity 'seroprevalence' named entity 'preprint' named entity 'serological' named entity 'asymptomatic' named entity 'consent form' named entity 'epidemic' named entity 'preprint' named entity '95% CI' named entity 'medRxiv' named entity 'Geneva' named entity 'medRxiv' named entity 'COVID' named entity '10.15' named entity 'medRxiv' named entity 'informed consent' named entity 'seroprevalence' named entity 'immunological' named entity 'randomly selected' named entity 'WHO' named entity 'CC-BY-NC-ND 4.0' named entity 'seroprevalence'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software